{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:13:54Z","timestamp":1788552834905,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82601457"],"award-info":[{"award-number":["82601457"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300767"],"award-info":[{"award-number":["82300767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118405","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:11:20Z","timestamp":1788016280000},"page":"118405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-2702","authenticated-orcid":false,"given":"Hongtu","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2024","key":"10.1016\/j.bcp.2026.118405_b0005","first-page":"S117","article-title":"Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2026.118405_b0010","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes, 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026, Diabetes Care 49 (2026) S246-S260. https:\/\/doi.org\/10.2337\/dc26-S011.","DOI":"10.2337\/dc26-S011"},{"issue":"2022","key":"10.1016\/j.bcp.2026.118405_b0015","first-page":"S1","article-title":"Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group, KDIGO","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2026.118405_b0020","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: a Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2026.118405_b0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0035","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118405_b0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0045","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1681\/ASN.0000000000000444","article-title":"Selonsertib in patients with diabetic kidney disease: a phase 2b randomized active run-in clinical trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0050","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543784.2025.2500294","article-title":"Endothelin receptor antagonists for diabetic kidney disease: back to the future?","volume":"34","author":"Anyfanti","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bcp.2026.118405_b0055","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0060","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0065","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med 369"},{"key":"10.1016\/j.bcp.2026.118405_b0070","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/ndt\/gfac242","article-title":"Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study","volume":"38","author":"Nangaku","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2026.118405_b0075","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118405_b0080","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118405_b0085","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2026.118405_b0090","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","article-title":"Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney failure: Implications for phase 2 Clinical Trials in CKD","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0100","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202202013RR","article-title":"Single-cell RNA-seq with spatial transcriptomics to create an atlas of human diabetic kidney disease","volume":"37","author":"Chen","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.118405_b0105","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41588-024-01802-x","article-title":"Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression","volume":"56","author":"Abedini","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2026.118405_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154862","article-title":"CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products","volume":"116","author":"Tu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.118405_b0115","article-title":"Experimental and data analysis advances in thermal proteome profiling","volume":"4","author":"Figueroa-Navedo","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.bcp.2026.118405_b0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2026.118405_b0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10157-023-02376-4","article-title":"eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from the Japan Chronic Kidney Disease Database","volume":"27","author":"Itano","year":"2023","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0130","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s00125-024-06210-8","article-title":"Spatial proteomics of human diabetic kidney disease, from health to class III","volume":"67","author":"Kondo","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2026.118405_b0135","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s41586-026-10363-4","article-title":"Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup","volume":"653","author":"Dumoulin","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118405_b0140","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000001053","article-title":"Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease","author":"Hu","year":"2026","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0145","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","article-title":"Upcoming drug targets for kidney protective effects in chronic kidney disease","volume":"40","author":"Nardone","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2026.118405_b0150","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.1038\/s41467-025-62101-5","article-title":"Urinary Complement proteome strongly linked to diabetic kidney disease progression","volume":"16","author":"Md Dom","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118405_b0155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12882-025-04166-4","article-title":"Plasma proteome signatures of ASK1 inhibition by selonsertib associate with efficacy in the MOSAIC randomized trial for diabetic kidney disease","volume":"26","author":"Petrovic","year":"2025","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","article-title":"Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in patients with CKD","volume":"35","author":"Smeijer","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s43188-024-00272-x","article-title":"Oxidative stress and NRF2 signaling in kidney injury","volume":"41","author":"Ng","year":"2025","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.bcp.2026.118405_b0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2026.118405_b0175","doi-asserted-by":"crossref","unstructured":"R.L. Gurung, H. Zheng, H.W.L. Koh, Y. M, J.J. Liu, S. Liu, C. Chan, K. Ang, C.S.H. Tan, R.M. Sobota, et al., Plasma Proteomics of Diabetic Kidney Disease Among Asians With Younger-Onset Type 2 Diabetes, J Clin Endocrinol Metab 110 (2025) e239-e248. https:\/\/doi.org\/10.1210\/clinem\/dgae266.","DOI":"10.1210\/clinem\/dgae266"},{"key":"10.1016\/j.bcp.2026.118405_b0180","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0185","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with Chronic Kidney Disease","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med 388"},{"key":"10.1016\/j.bcp.2026.118405_b0195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-Term Effects of Empagliflozin in patients with Chronic Kidney Disease","author":"EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med 392"},{"key":"10.1016\/j.bcp.2026.118405_b0200","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0205","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0210","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118405_b0215","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118405_b0220","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in patients with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): a Randomized Clinical Trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bcp.2026.118405_b0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2026.118405_b0230","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118405_b0235","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"B\u00f6hm","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118405_b0240","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000346948","article-title":"Rationale and trial design of Bardoxolone Methyl Evaluation in patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal events (BEACON)","volume":"37","author":"de Zeeuw","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0245","doi-asserted-by":"crossref","unstructured":"K. Yoshioka, H. Kaneko, W. Haruyama, T. Tomiyama, A. Takami, T. Kitayama, K. Yamasaki, Multi-Omics Reveal Antioxidant Effects of Bardoxolone Methyl in the Phase 2 Study of Bardoxolone Methyl in Patients with CKD and Type 2 Diabetes Study, Kidney360 6 (2025) 1880-1889. https:\/\/doi.org\/10.34067\/KID.0000000853.","DOI":"10.34067\/KID.0000000853"},{"key":"10.1016\/j.bcp.2026.118405_b0250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0255","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.13245","article-title":"Rationale and protocol of the Study of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy","volume":"20","author":"Heerspink","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2026.118405_b0260","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfad183","article-title":"Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial","volume":"39","author":"Heerspink","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcp.2026.118405_b0265","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"GS-US-223-1015 investigators, Effects of Selonsertib in patients with Diabetic Kidney Disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0270","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bcp.2026.118405_b0275","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/j.ajkd.2011.06.020","article-title":"Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial","volume":"58","author":"Lewis","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bcp.2026.118405_b0280","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0290","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1681\/ASN.2011111097","article-title":"Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy","volume":"23","author":"Chen","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2026.118405_b0295","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","article-title":"An atlas of healthy and injured cell states and niches in the human kidney","author":"Lake","year":"2023","journal-title":"Nature 619"},{"key":"10.1016\/j.bcp.2026.118405_b0300","doi-asserted-by":"crossref","first-page":"19619","DOI":"10.1073\/pnas.1908706116","article-title":"The single-cell transcriptomic landscape of early human diabetic nephropathy","volume":"116","author":"Wilson","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118405_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091227","article-title":"Oxidative stress and NRF2\/KEAP1\/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives","volume":"12","author":"Tanase","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2026.118405_b0310","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad38df","article-title":"Advancing preclinical drug evaluation through automated 3D imaging for high-throughput screening with kidney organoids","volume":"16","author":"Oishi","year":"2024","journal-title":"Biofabrication"},{"key":"10.1016\/j.bcp.2026.118405_b0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12882-025-04566-6","article-title":"Analysis of high glucose injury using human induced pluripotent stem cell-derived kidney organoids","volume":"27","author":"Qian","year":"2026","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13104-023-06303-4","article-title":"An animal-free preclinical drug screening platform based on human precision-cut kidney slices","volume":"16","author":"Mutsaers","year":"2023","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.bcp.2026.118405_b0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26093940","article-title":"Applications of the Cellular thermal Shift Assay to Drug Discovery in Natural Products: a Review","volume":"26","author":"Song","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118405_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2025.108380","article-title":"Thermal shift assays in drug discovery - Troubleshooting from biochemical to cellular applications","volume":"135","author":"Hanke","year":"2025","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bcp.2026.118405_b0335","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1073\/pnas.0910040106","article-title":"Target identification using drug affinity responsive target stability (DARTS)","volume":"106","author":"Lomenick","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118405_b0340","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","author":"Jafari","year":"2014","journal-title":"Nat Protoc 9"},{"key":"10.1016\/j.bcp.2026.118405_b0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-0716-3457-8_5","article-title":"Thermal Proteome Profiling for Drug Target Identification and probing of Protein States","volume":"2718","author":"Sauer","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118405_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114798","article-title":"Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: Principles and application","volume":"194","author":"Ren","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118405_b0355","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cpt.3237","article-title":"Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level","volume":"115","author":"Cho","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118405_b0360","doi-asserted-by":"crossref","DOI":"10.1159\/000547867","article-title":"NURTuRE-CKD academic steering group, Plasma and Urinary KIM-1 in Chronic Kidney Disease: Prognostic Value, Associations with Albuminuria, and Implications for Kidney failure and Mortality","author":"McDonnell","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bcp.2026.118405_b0365","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ekir.2025.04.061","article-title":"Complement Proteins Identify Rapidly Progressive Diabetic Kidney Disease","volume":"10","author":"Yun","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bcp.2026.118405_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14101054","article-title":"The potential use of Targeted Proteomics and Metabolomics for the Identification and monitoring of Diabetic Kidney Disease","volume":"14","author":"Van Roy","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.bcp.2026.118405_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100921","article-title":"Proteomics and Incident Kidney failure in individuals with CKD: the African American Study of Kidney Disease and Hypertension and the Boston Kidney Biopsy Cohort","volume":"6","author":"Chen","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.bcp.2026.118405_b0380","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1111\/dom.70153","article-title":"Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger-onset type 2 diabetes","volume":"27","author":"Gurung","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2026.118405_b0385","article-title":"Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes patients","volume":"9","author":"Peng","year":"2022","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bcp.2026.118405_b0390","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s00125-021-05444-0","article-title":"Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease","volume":"64","author":"Chan","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2026.118405_b0395","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.2040-1124.2012.00233.x","article-title":"Significance of renal biopsy in patients with presumed diabetic nephropathy","volume":"4","author":"Harada","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.bcp.2026.118405_b0400","doi-asserted-by":"crossref","unstructured":"S.F. Sanghavi, T. Roark, L.R. Zelnick, B. Najafian, N.K. Andeen, C.E. Alpers, R. Pichler, E. Ayers, I.H. de Boer, Histopathologic and Clinical Features in Patients with Diabetes and Kidney Disease, Kidney360 1 (2020) 1217-1225. https:\/\/doi.org\/10.34067\/KID.0003962020.","DOI":"10.34067\/KID.0003962020"},{"key":"10.1016\/j.bcp.2026.118405_b0405","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ekir.2021.01.025","article-title":"The Role of Glomerular Epithelial Injury in Kidney Function Decline in patients with Diabetic Kidney Disease in the TRIDENT Cohort","volume":"6","author":"Palmer","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.bcp.2026.118405_b0410","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/ki.1995.493","article-title":"Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression","volume":"48","author":"Fioretto","year":"1995","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2026.118405_b0415","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/nep.14338","article-title":"The renal apical sodium-dependent bile acid transporter expression rescue attenuates renal damage in diabetic nephropathy via farnesoid X receptor activation","volume":"29","author":"Li","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.bcp.2026.118405_b0420","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/s41401-023-01140-4","article-title":"Satellite cell-derived exosome-mediated delivery of microRNA-23a\/27a\/26a cluster ameliorates the renal tubulointerstitial fibrosis in mouse diabetic nephropathy","volume":"44","author":"Ji","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118405_b0425","article-title":"Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis","volume":"21","author":"Ding","year":"2023","journal-title":"Mater. Today Bio"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226007446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:35:40Z","timestamp":1788550540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226007446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":85,"alternative-id":["S0006295226007446"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118405","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118405"}}